{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T18:00:07Z","timestamp":1762711207323,"version":"build-2065373602"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,9]]},"DOI":"10.7759\/cureus.96433","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T17:51:31Z","timestamp":1762710691000},"source":"Crossref","is-referenced-by-count":0,"title":["Rituximab-Based Management of Autoimmune Blistering Diseases: A Case Series Highlighting Ocular and Systemic Presentations"],"prefix":"10.7759","author":[{"given":"Sebasti\u00e1n J","family":"V\u00e1zquez-Folch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel A","family":"Jim\u00e9nez-Berr\u00edos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor J","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalio","family":"Izquierdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Cicatricial pemphigoid","author":"Tolaymat L","year":"2025","unstructured":"Tolaymat L, Syed HA, Hall MR. Cicatricial pemphigoid. StatPearls. StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2015.11.006","article-title":"Autoimmune bullous diseases with skin and eye involvement: cicatricial pemphigoid, pemphigus vulgaris, and pemphigus paraneoplastica","volume":"34","author":"Broussard KC","year":"2016","unstructured":"Broussard KC, Leung TG, Moradi A, Thorne JE, Fine JD. Autoimmune bullous diseases with skin and eye involvement: cicatricial pemphigoid, pemphigus vulgaris, and pemphigus paraneoplastica. Clin Dermatol. 2016, 34:205-13. 10.1016\/j.clindermatol.2015.11.006","journal-title":"Clin Dermatol"},{"key":"ref3","unstructured":"DermNet. Pemphigus vulgaris. (2019). https.\/\/dermnetnz.org\/topics\/pemphigus-vulgaris."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12276753","article-title":"Definition of bullous pemphigoid antibody binding to intracellular and extracellular antigen associated with hemidesmosomes","volume":"92","author":"Mutasim DF","year":"1989","unstructured":"Mutasim DF, Morrison LH, Takahashi Y, Labib RS, Skouge J, Diaz LA, Anhalt GJ. Definition of bullous pemphigoid antibody binding to intracellular and extracellular antigen associated with hemidesmosomes. J Invest Dermatol. 1989, 92:225-30. 10.1111\/1523-1747.ep12276753","journal-title":"J Invest Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00136","article-title":"Pemphigus\u2014a disease of desmosome dysfunction caused by multiple mechanisms","volume":"9","author":"Spindler V","year":"2018","unstructured":"Spindler V, Waschke J. Pemphigus\u2014a disease of desmosome dysfunction caused by multiple mechanisms. Front Immunol. 2018, 9:136. 10.3389\/fimmu.2018.00136","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00692","article-title":"Autoantibody signaling in Pemphigus vulgaris: development of an integrated model","volume":"9","author":"Sajda T","year":"2018","unstructured":"Sajda T, Sinha AA. Autoantibody signaling in Pemphigus vulgaris: development of an integrated model. Front Immunol. 2018, 9:692. 10.3389\/fimmu.2018.00692","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-012615-044313","article-title":"Mechanisms of disease: pemphigus and bullous pemphigoid","volume":"11","author":"Hammers CM","year":"2016","unstructured":"Hammers CM, Stanley JR. Mechanisms of disease: pemphigus and bullous pemphigoid. Annu Rev Pathol. 2016, 11:175-97. 10.1146\/annurev-pathol-012615-044313","journal-title":"Annu Rev Pathol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/00130832-200410000-00017","article-title":"Ocular cicatricial pemphigoid review","volume":"4","author":"Foster CS","year":"2004","unstructured":"Foster CS, Sainz De La Maza M. Ocular cicatricial pemphigoid review. Curr Opin Allergy Clin Immunol. 2004, 4:435-9. 10.1097\/00130832-200410000-00017","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"ref9","unstructured":"Genentech. Phase III PEMPHIX study shows Genentech\u2019s Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris. (2019). Accessed. August 7, 2025: https:\/\/www.gene.com\/media\/press-releases\/14816\/2019-10-13\/phase-iii-pemphix-study-shows-genentechs."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.54","article-title":"Rituximab for patients with refractory mucous membrane pemphigoid","volume":"147","author":"Le Roux-Villet C","year":"2011","unstructured":"Le Roux-Villet C, Prost-Squarcioni C, Alexandre M, et al.. Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol. 2011, 147:843-9. 10.1001\/archdermatol.2011.54","journal-title":"Arch Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16678","article-title":"Efficacy and safety of biological agents for pemphigoid: a\u00a0systematic review and meta-analysis","volume":"62","author":"Lin Z","year":"2023","unstructured":"Lin Z, Zhao Y, Li F, Li J, Huang X. Efficacy and safety of biological agents for pemphigoid: a\u00a0systematic review and meta-analysis. Int J Dermatol. 2023, 62:1000-8. 10.1111\/ijd.16678","journal-title":"Int J Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/398497-rituximab-based-management-of-autoimmune-blistering-diseases-a-case-series-highlighting-ocular-and-systemic-presentations","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T17:51:32Z","timestamp":1762710692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/398497-rituximab-based-management-of-autoimmune-blistering-diseases-a-case-series-highlighting-ocular-and-systemic-presentations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,9]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.96433","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,9]]}}}